Sequence: YARAAARQARAC
| Experiment Id | EXP002418 |
|---|---|
| Paper | A cell-penetrating phospholamban-specific RNA aptamer enhances Ca2+ transients and contractile funct |
| Peptide | modified TAT (mTAT) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | ~2.5–5 µM mTAT–RNA-Apt30 |
| Rna Concentration | ~2.5–5 µM |
| Mixing Ratio | 1:1 covalent conjugate |
| Formulation Format | CPP–aptamer covalent conjugate |
| Formulation Components | mTAT peptide + RNA-Apt30 |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | Adult rat ventricular cardiomyocytes |
| Animal Model | |
| Administration Route | cell culture incubation |
| Output Type | Ca2+ transients and contractile function |
| Output Value | ↑ Ca2+ transient amplitude; ↑ sarcomere shortening; ↑ SERCA2a activity |
| Output Units | |
| Output Notes | Functional intracellular delivery of aptamer demonstrated; multiple aptamer sequences screened (Table 1), RNA-Apt30 selected for delivery studies |
| Toxicity Notes | No cytotoxicity reported |
| Curation Notes |